IDN Profiles are part of Healthbase, which is an innovative platform that helps multi-disciplinary market access teams navigate the complex healthcare ecosystem with the affiliations data and insights they need to ascertain the level of control IDNs exert and understand their alignment with physicians down to the individual provider level.
Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2
Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...
Biosimilars - Current Treatment - Oncology
In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launch...
Biosimilars - Current Treatment - Biosimilar Target Product Profiles (Oncology)
To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists
Biosimilars - Market Events And Forecast - Oncology
In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and Jap...